Sat.Dec 04, 2021 - Fri.Dec 10, 2021

article thumbnail

A serial biotech entrepreneur launches his next startup with high-dollar backing

Bio Pharma Dive

Founded and led by Gary Glick, Odyssey Therapeutics has raised $218 million in an initial fundraising round for its cancer and inflammatory disease drug research.

Drugs 352
article thumbnail

Biogen: This train wreck was due

World of DTC Marketing

MY POINT : Success is always temporary. When all is said and one, the only thing you’ll have left is your character. Right now, I could make a great argument that Biogen’s character is trashed and that they are a company in dire need of authentic leadership. Massive layoffs could be headed to Biogen due to the disappointing rollout of its Alzheimer’s drug Aduhelm that generated only a few million dollars in revenue over the past two quarters.

Drugs 231
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

WHO says vaccines should be effective against Omicron variant

Pharma Times

A senior official at the World Health Organisation (WHO) has said that Omicron is ‘highly unlikely’ to fully bypass vaccine protections.

article thumbnail

Is artificial intelligence the best tool for drug discovery?

Outsourcing Pharma

According to a leader from Cytoreason, AI isnât necessarily the best or only tool suited to discover new and novel therapiesâit might take a human touch.

Drugs 145
article thumbnail

Bridging Innovation & Patient Care: The Growing Role of AI

Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.

AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!

article thumbnail

A high-profile gene therapy biotech takes aim at Huntington's

Bio Pharma Dive

Passage Bio and the University of Pennsylvania's Gene Therapy Program said they have begun preclinical research aimed at simultaneously developing multiple approaches to treating Huntington's.

article thumbnail

How much should I spend on an HCP website?

World of DTC Marketing

LEAD-IN- Recent data confirms that health care professionals are using the Internet more and spending less time with drug company reps. How much should you spend on an HCP portal, and how do you measure its success? One of the first questions I often get from potential clients is, “how much does a good HCP website cost?” There is no one answer to that question.

Branding 213

More Trending

article thumbnail

Digital health firm Pear goes public, raising $175 million

pharmaphorum

Pear Therapeutics has completed its merger with blank cheque company Thimble Point Acquisition Corp, claiming a Nasdaq listing and raising $175 million in gross proceeds for the digital health specialist. Pear will make its debut on the exchange today after combining with Thimble Point – a special purpose acquisition company (SPAC) – in a deal that sidestepped the conventional initial public offering (IPO) route and has propelled its valuation to around $1.6 billion.

article thumbnail

Fresh data show UniQure's hemophilia gene therapy appears to hold up

Bio Pharma Dive

The amount of blood clotting protein found in patients who received the medicine was nearly the same at six months and 18 months post-treatment, according to results disclosed Thursday.

article thumbnail

Do you have enough money to launch your drug?

World of DTC Marketing

LEAD IN: Pharma budgets are being scrutinized like never before, and DTC/HCP marketers must justify every dollar spent. I’m getting more requests to measure and justify spending for specific bucket tactics, and I believe once politicians get focused, they will scrutinize drug pricing and force negotiations with Medicare tightening internal expenditures even more.

Drugs 204
article thumbnail

NHS waiting times reach record high of nearly six million

Pharma Times

In October 2021, over 356,000 people in England had been waiting for over six weeks for a key diagnostic test

130
130
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Abu Dhabi to Strengthen its Capabilities as a Life Sciences Hub Through a Pharma Collaboration with Belgium

Pharma Mirror

UAE, Abu Dhabi , Abu Dhabi has set its sights on Belgium, as a leading global pharmaceutical hub, to establish a global distribution corridor to serve the world in vaccine delivery and future life science needs. The collaboration builds on the capabilities of Abu Dhabi’s healthcare sector as a leading life sciences hub and the efforts of the HOPE Consortium in providing vaccine solutions for the world.

article thumbnail

Vaccine from Medicago, GSK protective against COVID-19 in large study

Bio Pharma Dive

The vaccine, which Medicago plans to soon submit to Canadian regulators, would be the first of its type, though supply appears likely to be limited.

article thumbnail

ACT for ALS Passes House while BrainStorm Prepares Moves Ahead with NurOwn

BioSpace

?A U.S. Congress subcommittee unanimously approved the ACT for ALS bill in a decision that could soon pour massive funding into the search for treatment for this debilitating and deadly disease.

126
126
article thumbnail

CHMP recommend approval for Roche’s COVID-19 therapy

Pharma Times

According to clinical data, Roche’s new COVID-19 treatment Actemra/RoActemra lowered mortality risk in critically ill adult patients.

130
130
article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

Distributed Control System Facilitates Expansion for New Drugs Produced by Contract Manufacturing Organization

Pharma Mirror

Combatting the pandemic has highlighted the importance of the partnership between biopharma organizations and the contract manufacturing organizations (CMOs) that must flexibly handle outsourced production, which can come suddenly and often must quickly be ramped up. For example, to meet the urgent need for COVID-19 related therapies and vaccines early in the pandemic, Thermo Fisher Scientific, a world leader in serving science with annual revenue of approximately $35 billion, had to expand its

article thumbnail

Latest Roche results show promise for new type of cancer immunotherapy

Bio Pharma Dive

Updated Phase 2 data suggested an experimental drug targeting the protein TIGIT could bolster the benefit of Roche's Tecentriq in certain people with advanced lung cancer.

Protein 324
article thumbnail

Cambya Sugar Substitute Lets People Have Their Cake and Eat it Too

XTalks

B.T. Sweet, an Israeli food tech startup, recently unveiled a plant-based, one-to-one drop-in sugar substitute called Cambya. It can replace sugar in a multitude of applications in the chocolate and confectionary space, boasting the same levels of sweetness and body as real sugar. So, what is Cambya and what differentiates it from other sugar substitutes?

Branding 121
article thumbnail

UK study shows mixing Pfizer and AstraZeneca COVID-19 vaccines with Moderna elicits better immune response

Pharma Times

Results show support in favour of heterologous dosing which may help to advance vaccination programmes in poorer countries.

article thumbnail

The New Age of Decentralized Clinical Trials

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations

article thumbnail

New Study: Fat Cells Are a Reservoir for COVID-19 Infection

BioSpace

Researchers published a study proving that SARS-CoV-2 infects human adipose or fat tissue to multiply and elicit an inflammatory response corresponding with severe COVID-19.

Research 112
article thumbnail

Lilly deepens research ties in China with biotech deal

Bio Pharma Dive

The collaboration with Regor Therapeutics is another example of large pharma companies' interest in partnering with emerging biotechs from China.

article thumbnail

The Impossible Cheeseburger Claimed the Top Spot on Grubhub’s “Year in Food” Report

XTalks

Each year, food delivery platform Grubhub releases its “Year in Food” report, which analyzes millions of deliveries and highlights top orders. This year, the Impossible Cheeseburger made with plant-based ingredients beat out the spicy chicken sandwich for the top order position, increasing in popularity by 442 percent in 2021. Here are some more notable statistics from Grubhub’s “Year in Food” report.

Protein 105
article thumbnail

Next virus could be more lethal than COVID-19, warns Oxford vaccine creator

Pharma Times

With the emergence of the new Omicron variant bringing into question the effectiveness of current vaccines, scientists caution that viruses will continue to evolve.

Vaccine 129
article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

Report: Biogen Eyes Massive Layoffs in Wake of Disappointing Aduhelm Rollout

BioSpace

The company could lay off as many as 1,000 employees as it continues to deal with the controversial treatment.

108
108
article thumbnail

AstraZeneca wagers $200M on Ionis' next chance at a rare disease drug

Bio Pharma Dive

The alliance follows AstraZeneca's buyout of Alexion last year and puts the British drugmaker in competition with Alnylam, Bridgebio and several others.

Drugs 319
article thumbnail

Consumer health innovation – where passion and science meet

pharmaphorum

Heather Barnes, external innovation lead EMEA at Johnson and Johnson Consumer Health, is a scientist who is truly passionate about consumer health. With her background in biochemistry and eye for identifying innovation trends, the future is bright at Johnson & Johnson Innovation. After making her way from early-stage drug development research to her current role, Heather got straight to work on creating sustainable collaborations that made life better for people and their families.

Allergies 105
article thumbnail

Health minister welcomes new treatments for COVID-19 patients

Pharma Times

The treatments are being offered as an addition to vaccinations to maximise protection against COVID-19

Vaccine 123
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

Cincinnati Children’s Hospital and CTI create joint venture for cell and gene therapy manufacturing

BioPharma Reporter

Cincinnati Children's Hospital Medical Center and research service provider CTI Clinical Trial & Consulting Services will form a company to provide cell and gene therapy manufacturing services to the biotech and pharmaceutical industries.

article thumbnail

Martin Shkreli's former company to pay $40M in settlement over drug price hikes

Bio Pharma Dive

The payment resolves the government's claims against Vyera and Phoenixus for their efforts to block competition to Daraprim, the toxoplasmosis drug Shkreli famously raised the price of by 4,000%.

Drugs 303
article thumbnail

Mind the gap: Are you delivering what HCPs value or what you want them to have?

pharmaphorum

Since the onset of the Covid-19 pandemic, life science companies have acted quickly to address the evolving digital needs of healthcare professionals, with mixed success (see graph 1). In the age of information overload, we all know that it is essential to add ‘value’ if we are to cut through the noise. And therein lies an issue. In a recent study by EPG Health, pharma respondents voted ‘providing real value’ the top challenge (of 23) related to digital Health Care Provider (HCP) engagement.

article thumbnail

NICE publish final guidance recommending Aspaveli in adults with ultra-rare blood disorder

Pharma Times

The drug is additionally undergoing assessment with the Medicines and Healthcare products Regulatory Agency for a marketing authorisation in the UK

Medicine 123
article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time